In a retrospective study at Georgetown Lombardi Cancer Center, inactive melanoma confirmed by PET/CT or tumor biopsy had a relapse rate of less than 10% at one year after anti-PD-1 withdrawal (138). This evidence concerns the gene PDCD1 and neoplasm.